MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$15,721K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturity and redem...
Accrued expenses and other curre...
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchase of marketable debt secu...
Purchase of property and equipme...
Operating lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-21,668
-17,782
-17,307
-13,258
Stock-based compensation
1,384
1,362
1,043
1,047
Operating lease right-of-use asset
289
283
278
273
Depreciation
72
90
93
88
Realized loss (gain) on redemption of marketable debt securities
-
-
9
-
Amortization of premium (accretion of discount) on marketable debt securities
-169
-190
-317
-396
Prepaid expenses and other current assets
-965
261
976
99
Other assets
-60
3,030
-60
-58
Accounts payable
243
1,089
-1,562
-795
Accrued expenses and other current liabilities
3,743
-2,602
2,044
922
Operating lease liabilities
-308
-302
-297
-292
Net cash provided by (used in) operating activities
-15,389
-21,343
-16,950
-12,452
Purchase of marketable debt securities
19,233
43,857
62,708
24,412
Proceeds from maturity and redemption of marketable debt securities
37,319
29,136
35,824
17,910
Purchase of property and equipment
332
-
24
4
Net cash provided by (used in) investing activities
17,754
-14,721
-26,908
-6,506
Proceeds from exercise of underwriters option in december 2024 public offering, net of offering costs of 214
-
-
0
2,528
Offering costs paid in connection with public offerings
0
526
0
0
Proceeds from exercise of warrants
-
-
1
-
Proceeds from december 2025 public offering, net of offering costs of 5,286
-
-
80,964
-
Proceeds from exercise of pre-funded warrants
-
-
-
0
Proceeds from exercise of stock options
-
-
0
13
Proceeds from exercise of warrants
0
1,942
-
-
Taxes paid related to net share settlement of restricted stock units
26
272
0
0
Net cash provided by (used in) financing activities
-26
1,144
80,964
13
Net increase (decrease) in cash and cash equivalents and restricted cash
2,339
-34,920
37,106
-18,945
Cash and cash equivalents and restricted cash - beginning of period
13,296
13,296
-
163,543
Cash and cash equivalents and restricted cash - end of period
17,821
-
-
-
Proceeds from exercise of stock options included in other current assets and additional paid-in-capital
412
-
-
-
Cash and cash equivalents
17,076
-
-
-
Restricted cash, non-current
745
-
-
-
Cash and cash equivalents and restricted cash
17,821
15,482
-
13,296
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturity
and redemption of...
$37,319K
(224.51%↑ Y/Y)
Net cash provided by
(used in) investing...
$17,754K
(116.74%↑ Y/Y)
Canceled cashflow
$19,565K
Net increase
(decrease) in cash and cash...
$2,339K
(101.78%↑ Y/Y)
Canceled cashflow
$15,415K
Purchase of marketable
debt securities
$19,233K
(-83.63%↓ Y/Y)
Purchase of property and
equipment
$332K
(403.03%↑ Y/Y)
Accrued expenses and
other current...
$3,743K
(274.50%↑ Y/Y)
Stock-based compensation
$1,384K
(-20.28%↓ Y/Y)
Prepaid expenses and
other current assets
-$965K
(-195.36%↓ Y/Y)
Operating lease
right-of-use asset
$289K
(-45.47%↓ Y/Y)
Accounts payable
$243K
(-83.63%↓ Y/Y)
Depreciation
$72K
(-60.22%↓ Y/Y)
Other assets
-$60K
(70.59%↑ Y/Y)
Net cash provided by
(used in) operating...
-$15,389K
(42.93%↑ Y/Y)
Net cash provided by
(used in) financing...
-$26K
(-101.50%↓ Y/Y)
Canceled cashflow
$6,756K
Net income (loss)
-$21,668K
(19.37%↑ Y/Y)
Taxes paid related to
net share...
$26K
(-85.95%↓ Y/Y)
Operating lease
liabilities
-$308K
(42.43%↑ Y/Y)
Amortization of premium
(accretion of discount) on...
-$169K
(68.23%↑ Y/Y)
Buy us a coffee
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)